GSK2190915 Pediatric Study

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01286844
First received: October 7, 2010
Last updated: June 9, 2011
Last verified: March 2011
  Purpose

GSK2190915 is under development as an oral controller for the treatment of adult and pediatric asthma. This study is an open label, single and repeat dose escalation study, in children with asthma. It will investigate the pharmacokinetics of GSK2190915 in children, aged from 1 to 12 years old inclusive, to determine how the dosage regimen for GSK2190915 in a pediatric population should be adjusted to achieve approximately the same level of systemic exposure that is safe and effective in adults.


Condition Intervention Phase
Asthma
Drug: GSK2190915A 5mg
Drug: GSK2190915A 10mg
Drug: GSK2190915A 25mg
Drug: GSK2190915A 50mg
Drug: GSK2190915A 100mg
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Dose Escalation Study to Examine the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of Single and Repeat Oral Doses of GSK2190915 in Children Aged From 1 to 11 Years With Asthma

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Derived plasma pharmacokinetic parameters [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Leukotriene biomarkers [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
  • Vital Signs [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
  • ECG [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
  • Adverse Event Monoitoring [ Time Frame: Up to 90 days ] [ Designated as safety issue: Yes ]
  • Clinical Labs [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 32
Study Start Date: November 2010
Estimated Study Completion Date: May 2011
Estimated Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
Subjects ≥4 and< 12 years. First 6 subjects included, ≥8 and< 12 yrs and weigh ≥21kg, receive 1 SD (10mg) and an 8 day RD period (100mg). Remaining subjects in cohort: Subjects < 21kg receive 2 SD periods (10mg and 50mg), Subjects > 21kg receive 2 SD periods (10mg and 50mg) and an 8 day RD (100mg)
Drug: GSK2190915A 10mg
Oral powder for dispersion in water
Drug: GSK2190915A 50mg
Oral powder for dispersion in water
Drug: GSK2190915A 100mg
Oral powder for dispersion in water
Experimental: Cohort 2
Subjects ≥1 and< 4 years, receive 2 SD (5mg and 25mg)
Drug: GSK2190915A 5mg
Oral powder for dispersion in water
Drug: GSK2190915A 25mg
Oral powder for dispersion in water

Detailed Description:

Subjects will be recruited into 2 cohorts, Cohort 1 with children from 4 years of age to less than 12 years of age and cohort 2 with children from 1 year of age to less than 4 years of age. Cohort 1 is further subdivided, dependent on a subject's weight, which enables different dosing regimens and pharmacokinetic sampling within the cohort. There are 3 scheduled Pharmacokinetic and Safety Review meetings, which enable dose adjustment and dosing in the younger subjects through the study.

Blood and urine are collected for pharmacokinetic and pharmacodynamic analysis. Safety will be assessed by measurement of heart rate, blood pressure, ECG, safety laboratory data and review of adverse events. Subjects will also perform PEF and Spirometry if assessed as capable by the study investigator.

  Eligibility

Ages Eligible for Study:   1 Year to 11 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and pre-menarchial female subjects aged 1to <12 years at screening are eligible for this study.
  • Investigator diagnosed history of asthma.
  • Subject weight a minimum of 11kg and above the 10th percentile for their age.
  • Patients must be controlled on any existing asthma treatment or currently stable off treatment, at screening.
  • Apart from asthma, eczema and rhinitis, subjects should be healthy and suffer from no other significant medical conditions.
  • Subjects and parents/guardians must be able to understand and comply with protocol requirements, instructions and protocol-stated restrictions. Parents/guardians must have the ability to read and write.

A signed and dated informed consent from at least one parent/guardian, and, for subjects ≥ 7 years old an accompanying informed assent from the subject prior to admission to the study.

- AST and ALT < 2xULN.

Exclusion Criteria:

  • Subjects who have changed their asthma medication, dose or regime within 4 weeks of screening
  • Administration of anti -leukotriene therapies for 14 days before screening and during the study.
  • Any medical condition or circumstance making the volunteer unsuitable for participation in the study.
  • Any clinically relevant abnormality identified on the screening medical assessment.
  • Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening and led to a change in asthma management.
  • Administration of any vaccinations within 2 weeks of screening or during the study
  • Parent/guardian has history of psychiatric disease, intellectual deficiency, substance abuse, or other condition which will limit the validity of consent to participate in this study.
  • Any adverse reaction including immediate or delayed hypersensitivity to any component of study drug
  • A subject will not be eligible for this study if he/she is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator.
  • Children who are wards of the state or government.
  • The subject has a screening QTc value of >450msec, PR interval outside the range 120 to 220msec or an ECG that is not suitable for QT measurements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01286844

Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT01286844     History of Changes
Other Study ID Numbers: 112361
Study First Received: October 7, 2010
Last Updated: June 9, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on August 20, 2014